Ranbaxy-Pfizer Settlement Could Set Indian Generics Trend
This article was originally published in PharmAsia News
The settlement between India's Ranbaxy Laboratories and U.S. drugmaker Pfizer could set a precedent for similar agreements between generics and brand-drug firms. Most of India's leading generics makers are involved in court battles over patents on branded drugs, spending $128.1 million on legal efforts. Because of the Pfizer-Ranbaxy settlement, other Indian generics may be more willing to reach out-of-court settlements. A Novartis India official said, "The trend is definitely going to catch on." (Click here for more
You may also be interested in...
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.
With the India business on the road to recovery and the US growth outlook muted, Torrent hopes to keep the boat steady in fiscal 2021. It also expects an order in Q3 in a patent infringement case pertaining to AstraZeneca’s Farxiga, where it and multiple Indian firms are seeking to launch generic versions.